Is Propanc Biopharma, Inc. (PPCB) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 64.4% / 30% | 0.5% / 30% | 0.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 64.4% / 33% | 0.5% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 8.8% / 33% | 0.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | 64.4% / 33% | 0.5% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 8.8% / 33% | 0.1% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -1811.7% | |
| Return on Assets (ROA) | -535.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$405,168 |
| Free Cash Flow | -$405,168 |
| Total Debt | $2M |
| Debt-to-Equity | 5.7 |
| Current Ratio | 2.1 |
| Total Assets | $20M |
Price & Trading
| Last Close | $0.11 |
| 50-Day MA | $0.20 |
| 200-Day MA | $2.18 |
| Avg Volume | 1.9M |
| Beta | 3.5 |
|
52-Week Range
$0.10
| |
About Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Propanc Biopharma, Inc. (PPCB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Propanc Biopharma, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Propanc Biopharma, Inc.'s debt ratio?
Propanc Biopharma, Inc.'s debt ratio is 64.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.8%.
What are Propanc Biopharma, Inc.'s key financial metrics?
Propanc Biopharma, Inc. has a market capitalization of $2M, trailing P/E ratio of 0.0. Return on equity stands at -1811.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.